PDT Partners’s Global Blood Therapeutics, Inc. GBT Stock Holding History

PDT Partners’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,730	Closed	-$551K	–	931
2020 Q4	$551K	Buy	+12,730	New	+$628K	0.04%	435
2018 Q2	–	Sell	-289,366	Closed	-$14M	–	598
2018 Q1	$14M	Buy	289,366 +15,212	+6%	+$849K	0.47%	64
2017 Q4	$10.8M	Sell	274,154 -7,446	-3%	-$278K	0.31%	114
2017 Q3	$8.74M	Hold	281,600	–	–	0.29%	123
2017 Q2	$7.7M	Buy	+281,600	New	+$8.38M	0.31%	119

Other funds holding GBT

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PDT Partners's GBT Position: Q1 2021 in Review

PDT Partners sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2021, closing a stake of 12,730 shares — an estimated $551K sold.

PDT Partners first reported a position in GBT in Q2 2017 and held it in 5 quarters. The position peaked at $14M in Q1 2018. 214 funds tracked by Wall St. Rank hold GBT as of Q1 2021.

PDT Partners reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
PDT Partners sold 12,730 Global Blood Therapeutics, Inc. shares in Q1 2021, an estimated $551K.
PDT Partners first reported a position in Global Blood Therapeutics, Inc. in Q2 2017 and held it in 5 quarters.
PDT Partners's Global Blood Therapeutics, Inc. position peaked at $14M in Q1 2018.
214 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2021.

Based on PDT Partners's 13F filing for Q1 2021, filed 17 May 2021.